Pancreatic Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Pancreatic Cancer, including details on symptoms, causes, treatment, information.

Volume 4 (2007), Issue 5 (May)

1. Phase II trial of infusional fluorouracil, leucovorin, mitomycin, and dipyridamole in locally advanced unresectable pancreatic adenocarcinoma: SWOG S9700.
   J Clin Oncol, 25(13): 1665-9. [Abstract] [Full-text]
2. 3,3',5-Triiodo-L-thyronine inhibits ductal pancreatic adenocarcinoma proliferation improving the cytotoxic effect of chemotherapy.
   J Endocrinol, 193(2): 209-23. [Abstract] [Full-text]
3. Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer.
   J Surg Oncol, 95(6): 507-12. [Abstract] [Full-text]
4. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis.
   JAMA, 297(17): 1901-8. [Abstract] [Full-text]
5. c-Myc-induced chemosensitization is mediated by suppression of cyclin D1 expression and nuclear factor-kappa B activity in pancreatic cancer cells.
   Clin Cancer Res, 13(9): 2811-21. [Abstract] [Full-text]
6. Mechanisms of synthetic serine protease inhibitor (FUT-175)-mediated cell death.
   Cancer, 109(10): 2142-53. [Abstract] [Full-text]
7. Phosphoinositide-3-kinase signaling controls S-phase kinase-associated protein 2 transcription via E2F1 in pancreatic ductal adenocarcinoma cells.
   Cancer Res, 67(9): 4149-56. [Abstract] [Full-text]
8. Antihypertensives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in pancreatic ductal adenocarcinoma.
   J Am Coll Surg, 204(5): 996-1005; discussion 1005-6. [Abstract] [Full-text]
9. Fate of the remnant pancreas after resection of noninvasive intraductal papillary mucinous neoplasm.
   J Am Coll Surg, 204(5): 987-93; discussion 993-5. [Abstract] [Full-text]
10. Incidence of additional primary cancers in patients with invasive intraductal papillary mucinous neoplasms and sporadic pancreatic adenocarcinomas.
    J Am Coll Surg, 204(5): 803-13; discussion 813-4. [Abstract] [Full-text]
11. The use of adjusted preoperative CA 19-9 to predict the recurrence of resectable pancreatic cancer.
    J Surg Res, 140(1): 31-5. [Abstract] [Full-text]
12. Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells.
    J Biol Chem, 282(19): 14048-55. [Abstract] [Full-text]
13. Estrogen receptor beta/alpha ratio predicts response of pancreatic cancer cells to estrogens and phytoestrogens.
    J Surg Res, 140(1): 55-66. [Abstract] [Full-text]
14. Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial.
    Cancer Chemother Pharmacol, 60(2): 295-303. [Abstract] [Full-text]
15. The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas.
    Gastroenterology, 132(6): 2208-25. [Abstract] [Full-text]
16. Evaluation of topoisomerase IIa expression in pancreatic ductal adenocarcinoma: a pilot study using chromogenic in situ hybridization and immunohistochemistry on tissue microarrays.
    Pancreatology, 7(1): 45-52. [Abstract] [Full-text]
17. Pancreaticoduodenectomy for peri-ampullary neoplasia leads to specific micronutrient deficiencies.
    Pancreatology, 7(1): 37-44. [Abstract] [Full-text]
18. Precursor lesions of pancreatic cancer: molecular pathology and clinical implications.
    Pancreatology, 7(1): 9-19. [Abstract] [Full-text]
19. Transient receptor potential channel TRPM8 agonists stimulate calcium influx and neurotensin secretion in neuroendocrine tumor cells.
    Neuroendocrinology, 85(2): 81-92. [Abstract] [Full-text]
20. Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma.
    Cancer, 109(8): 1561-9. [Abstract] [Full-text]
21. Development of indolequinone mechanism-based inhibitors of NAD(P)H:quinone oxidoreductase 1 (NQO1): NQO1 inhibition and growth inhibitory activity in human pancreatic MIA PaCa-2 cancer cells.
    Biochemistry, 46(20): 5941-50. [Abstract] [Full-text]
22. The role of protein kinases in pancreatic carcinogenesis.
    Clin Chim Acta, 381(1): 56-62. [Abstract] [Full-text]
23. SOCS1 silencing enhances antitumor activity of type I IFNs by regulating apoptosis in neuroendocrine tumor cells.
    Cancer Res, 67(10): 5025-32. [Abstract] [Full-text]
24. Molecular basis of the synergistic antiangiogenic activity of bevacizumab and mithramycin A.
    Cancer Res, 67(10): 4878-85. [Abstract] [Full-text]
25. HMGA1 controls transcription of insulin receptor to regulate cyclin D1 translation in pancreatic cancer cells.
    Cancer Res, 67(10): 4679-86. [Abstract] [Full-text]
26. Nationwide questionnaire survey of the contemporary surgical management of pancreatic cancer in the United Kingdom & Ireland.
    Int J Surg, 5(3): 147-51. [Abstract] [Full-text]
27. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.
    J Clin Oncol, 25(15): 1960-6. [Abstract] [Full-text]
28. Pancreatic carcinoma incidence and survival in Sweden in 1980-2000: a population-based study of 16,758 hospitalized patients with special reference to different therapies.
    Eur J Surg Oncol, 33(5): 616-22. [Abstract] [Full-text]
29. Imaging findings of leukemic involvement of the pancreaticobiliary system in adults.
    AJR Am J Roentgenol, 188(6): 1589-95. [Abstract] [Full-text]
30. Kallikrein 7 enhances pancreatic cancer cell invasion by shedding E-cadherin.
    Cancer, 109(9): 1811-20. [Abstract] [Full-text]
31. Expression of glucose transporter-1, hexokinase-II, proliferating cell nuclear antigen and survival of patients with pancreatic cancer.
    Cancer Invest, 25(3): 154-62. [Abstract] [Full-text]
32. Ribonucleotide reductase subunit M2 mRNA expression in pretreatment biopsies obtained from unresectable pancreatic carcinomas.
    J Gastroenterol, 42(5): 389-94. [Abstract] [Full-text]
33. Novel therapeutic approaches in the treatment of advanced pancreatic carcinoma.
    Cancer Treat Rev, 33(3): 289-98. [Abstract] [Full-text]
34. A phase I trial of S-1 with concurrent radiotherapy for locally advanced pancreatic cancer.
    Br J Cancer, 96(11): 1650-5. [Abstract] [Full-text]
35. Establishment of three-dimensional cultures of human pancreatic duct epithelial cells.
    Biochem Biophys Res Commun, 358(3): 698-703. [Abstract] [Full-text]
36. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group.
    J Clin Oncol, 25(16): 2212-7. [Abstract] [Full-text]
37. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells.
    Int J Cancer, 121(3): 656-65. [Abstract] [Full-text]

© 2004-2008 Pancreatic Cancer Research Today. All Rights Reserved.